Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children

Trial Profile

Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate
  • Indications Meningococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 Oct 2017 to 10 Nov 2017.
    • 18 Apr 2017 Planned primary completion date changed from 1 Oct 2017 to 10 Nov 2017.
    • 02 Nov 2014 Planned primary completion date changed from 1 Oct 2013 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top